By Fineline Cube 
China’s Drug Price Registration System officially launched today with the first batch of 10 drug products from nine pharmaceutical companies, including China Meheco, Tong Ren Tang, BeOne, Akeso, Yifan Pharma, Roche Pharma, JW Therapeutics, IASO Bio, and Hengrui Pharmaceuticals. The system enables voluntary price registration based on company development needs and establishes a dual pricing mechanism for pharmaceuticals.
First Batch Registrants & System Features
| Registrant Count | Companies | System Framework |
|---|---|---|
| 9 Companies | China Meheco, Tong Ren Tang, BeOne, Akeso, Yifan Pharma, Roche Pharma, JW Therapeutics, IASO Bio, Hengrui Pharmaceuticals | Voluntary Registration: Companies declare prices based on development needs |
| 10 Products | First batch of drug products | Price Authenticity: Companies responsible for declared price veracity |
| Operating Unit | Government agency | Non‑Interference: Accepts applications without influencing specific price levels |
Dual Pricing Mechanism & International Competitiveness
| Pricing System | Purpose | Key Characteristics |
|---|---|---|
| Public Market List Price | Transparent, comparable pricing for international comparison | Voluntarily registered by companies; represents true market pricing outside insurance settlements |
| Confidential Insurance Payment Price | Lower settlement price for domestic medical insurance | Independent from list price; does not change insured/uninsured patient price levels |
| International Practice | Strengthens Chinese pharma companies’ ability to participate in global competition | Two independent price sets, common in developed markets |
Market Impact & Strategic Implications
- Price Transparency: Registered prices provide benchmark for international price comparisons, enhancing global competitiveness
- Insurance Independence: System maintains existing insurance payment mechanisms while creating parallel market pricing
- Voluntary Participation: Companies can opt-in based on strategic needs, reducing regulatory burden
- Innovation Incentive: Transparent pricing may support premium pricing for innovative drugs in private markets
- Market Liberalization: Represents further shift toward market-driven pricing mechanisms in China’s healthcare sector
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation and market impact of China’s Drug Price Registration System. Actual outcomes may differ due to policy enforcement, industry adoption rates, and evolving regulatory frameworks.-Fineline Info & Tech